探索药物重定位治疗腹主动脉瘤:系统评价与荟萃分析
该系统评价与荟萃分析纳入39项研究、84个队列,评估重定位药物或膳食补充剂对腹主动脉瘤扩张、破裂或修复风险的影响。二甲双胍和他汀在延缓腹主动脉瘤生长上具统计学意义,但均无低偏倚风险研究且异质性极高(I²>80%),证据确定性均为极低。
要点
- 二甲双胍使用者与非使用者腹主动脉瘤直径年均增长差为-0.73 mm/年(排除高偏倚风险研究)。
- 他汀总体估计年均增长差为-0.84 mm/年,但无低偏倚风险研究且异质性极高。
- 二甲双胍和他汀的证据确定性均为极低,未发现任何研究药物的确定性证据。
核心结论
- 该系统评价与荟萃分析提示二甲双胍和他汀可能对延缓腹主动脉瘤进展有一定效果,但未发现本研究中任何研究药物的确定性证据,需更稳健方法学的进一步研究。
研究设计与样本
- 系统检索五个数据库,纳入观察性研究和随机对照试验,并纳入两项筛查试验的未发表数据。
- 共筛查7484项研究,39项符合纳入标准,未纳入膳食补充剂研究,从纳入研究中衍生84个队列。
- 对十二个不同药物组进行荟萃分析,按总体偏倚风险分层,偏倚风险采用纽卡斯尔-渥太华量表和修订版Cochrane偏倚风险工具评估。
- 结果按PRISMA指南报告。
主要发现
- 二甲双胍和他汀两个药物组在延缓腹主动脉瘤生长方面具统计学意义。
- 这两个药物组均无低偏倚风险研究,结果异质性极高(I²>80%),GRADE证据确定性均为极低。
- 二甲双胍排除高偏倚风险研究后,使用者与非使用者腹主动脉瘤直径估计年均增长差为-0.73 mm/年。
- 他汀总体估计年均增长差为-0.84 mm/年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 二甲双胍和他汀两个药物组均无低偏倚风险研究纳入。
- 这两个药物组结果的异质性极高(I²>80%)。
- 二甲双胍和他汀的GRADE证据确定性均为极低。
- 未发现本研究中任何研究药物的确定性证据。
- 需更稳健方法学的进一步研究以确定有效的腹主动脉瘤药物治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Large abdominal aortic aneurysms (AAAs) present a significant mortality risk. While numerous medical interventions have been proposed, no drugs have convincingly reduced AAA progression, rupture rates, or repair risk. This systematic review and meta-analysis aimed to assess the impact of re-purposed drugs or dietary supplements on slowing expansion rates, reducing the risk of rupture, or minimising the risk of repair for individuals with AAA. METHODS: A systematic search was conducted in five databases. Both observational studies and randomised controlled trials were included. Unpublished data from two screening trials were incorporated. Risk of bias was assessed using the Newcastle-Ottawa scale and revised Cochrane risk of bias tool. Meta-analyses were performed for each identified drug subclass and were stratified by overall risk of bias. Results were reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: Of 7 484 screened studies, 39 met the inclusion criteria. No studies on dietary supplements were included. A total of 84 cohorts were derived from the included studies, and twelve distinct drug groups underwent meta-analyses. Two drug groups, metformin and statins, were statistically significant in slowing AAA growth. No low risk of bias studies were included for these two drug groups, and the results had very high heterogeneity (I2 > 80%). Both groups had a GRADE certainty of very low. Metformin, excluding high risk of bias studies, presented an estimated mean growth difference of AAA diameter between users and non-users of -0.73 mm/year, whilst statins had an overall estimated mean difference of -0.84 mm/year. CONCLUSION: This systematic review and meta-analysis suggests that metformin and statins may provide some effect in slowing AAA progression. However, no definitive evidence was found for any of the investigated drugs included in this study. Further research is needed to identify effective medical treatments for AAA progression with more robust methodology.
引用
- Skovbo Kristensen JS, Krasniqi L, Obel LM, et al. Exploring Drug Re-Purposing for Treatment of Abdominal Aortic Aneurysms: a Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg. 2023. PMID: 38013062. doi:10.1016/j.ejvs.2023.11.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。